Antares Pharma, Inc (ATRS)

Etorro trading 970x250

About Antares Pharma, Inc

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address unmet needs in targeted therapeutic areas. It develops, manufactures, and commercialize novel therapeutic products using its drug delivery systems. The company’s injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and for glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto injectors; and drug/device product for urologic oncology and endocrinology. The company have strategic alliances and partnership arrangements pharmaceutical companies, including Pfizer, Idorsia, Teva, and AMAG. Antares Pharma, Inc. was founded in 1978 and is headquartered in Ewing, New Jersey. Address: 100 Princeton South, Ewing, NJ, United States, 08628

Antares Pharma, Inc News and around…

Latest news about Antares Pharma, Inc (ATRS) common stock and company :

FDA Grants Fast Track Tags To Drug Candidates For Antares Pharma, Celcuity, Celularity
18 Jan, 2022 FinancialContent

TheFDA has granted Fast Track designationtoAntares Pharma Inc's(NASDAQ: ATRS) for ATRS-1902 for adrenal ...

Antares Pharma Receives FDA Fast Track Designation for ATRS-1902 for Adrenal Crisis Rescue
18 Jan, 2022 Yahoo! Finance

EWING, N.J., Jan. 18, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that the U.S. Food and Drug Administration (“FDA”) has granted Fast Track designation for ATRS-1902 for adrenal crisis rescue. The development program for ATRS-1902 supports a proposed indication for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary auto-injector pla

Antares Pharma, Inc.'s (NASDAQ:ATRS) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
13 Jan, 2022 Yahoo! Finance

Most readers would already be aware that Antares Pharma's (NASDAQ:ATRS) stock increased significantly by 11% over the...

Antares Pharma Appoints Claude E. Richardson as Senior Vice President of Human Resources
12 Jan, 2022 Yahoo! Finance

EWING, N.J., Jan. 12, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, announced today the appointment of Claude E. Richardson as Senior Vice President of Human Resources. Mr. Richardson will be responsible for Antares’ corporate Human Resources (“HR”) strategy and development. Claude E. Richardson has more than 25 years of Human Resources leadership experience across multiple industries including pharmaceutical, industrials, finan

Antares Pharma Announces Positive Results From Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
11 Jan, 2022 Yahoo! Finance

EWING, N.J., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced positive results from a Phase I study for ATRS-1902 for adrenal crisis. The positive results support the advancement of the ATRS-1902 development program to a pivotal clinical study for the treatment of acute adrenal insufficiency, known as adrenal crisis, in adults and adolescents, using our Vai™ novel proprietary rescue pen platform to deliver

How The Pieces Add Up: SMLF Targets $66
27 Dec, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Multifactor ETF (SMLF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $66.49 per unit.

5 Value Stocks In The Healthcare Sector
20 Dec, 2021 FinancialContent

What is a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. ...

MedMira strengthen its Board with New Appointment
17 Dec, 2021 Yahoo! Finance

HALIFAX, Nova Scotia, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Today, MedMira Inc. (MedMira) (TSXV: MIR) announced today the appointment of Mr. Thomas Bergmann to the board effective immediately. Mr. Bergmann is the former CEO and Member of the Board of the US based pharmaceutical company Macromed Inc. which was sold to a publicly traded pharmaceutical company in the United Kingdom. Furthermore, he served as Chairman of the Board of BioEqual, a Swiss based development company for medical devices and of

The Daily Biotech Pulse: Calliditas Snags FDA Nod, Novartis to Buy Back $15B In Shares, Valneva Touts Vaccine Data, Immix, Bionomics Debut On Wall Street
16 Dec, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Calliditas Gets Conditional ...

Assertio Shares Gain After Buying Antares' Rheumatoid Arthritis Treatment For $44M
16 Dec, 2021 FinancialContent

Antares Pharma Inc(NASDAQ: ATRS) divested Otrexup (methotrexate) injection to treat rheumatoid arthritis to a subsidiary ...

Antares Pharma Announces Divestiture of Otrexup®
15 Dec, 2021 Yahoo! Finance

EWING, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the divestiture of OTREXUP® (methotrexate) injection for the treatment of rheumatoid arthritis to a subsidiary of Assertio Holdings, Inc., a commercial pharmaceutical company, for a total cash consideration of $44.0 million inclusive of OTREXUP® WIP and finished inventory. Under the terms of the asset purchase agreement, Antares will receive an i

If You Like EPS Growth Then Check Out Antares Pharma (NASDAQ:ATRS) Before It's Too Late
08 Dec, 2021 Yahoo! Finance

Like a puppy chasing its tail, some new investors often chase 'the next big thing', even if that means buying 'story...

Antares Pharma to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
22 Nov, 2021 Yahoo! Finance

EWING, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held on November 29-December 2, 2021. A pre-recorded webcast of the fireside chat will be available under the “For Investors” section of the Antares Pharma w

Overview Of Value Stocks In The Healthcare Sector
15 Nov, 2021 FinancialContent

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

LPCN: Third Quarter Update
11 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT Third Quarter 2021 Financial and Operational Results On November 10, 2021 Lipocine (NASDAQ:LPCN) filed its Form 10-Q and posted its earnings release for the three month period ending September 30, 2021. Highlights for the third quarter 2021 and to-date include: ➢ Settlement with Clarus Therapeutics - July 2021 ➢ LPCN 1144

Antares Pharma to Present at the Jefferies London Healthcare Conference
10 Nov, 2021 Yahoo! Finance

EWING, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that Robert F. Apple, President and Chief Executive Officer, is scheduled to virtually present and host investor meetings at the Jefferies London Healthcare Conference being held November 16-19, 2021. Details of the presentation are as follows: Event:Jefferies London Healthcare ConferenceFormat:Fireside Chat and 1x1 MeetingsPresentation Date:Nove

LPCN: Antares Agreement & NASH Fast Track Change the Calculus
08 Nov, 2021 Yahoo! Finance

By John Vandermosten, CFA NASDAQ:LPCN READ THE FULL LPCN RESEARCH REPORT TLANDO Licensing Agreement with Antares Pharma On October 18th, Lipocine (NASDAQ:LPCN) announced that it had entered into a licensing agreement with Antares Pharma. The agreement is for commercialization of TLANDO in the US and includes the following terms: ➢ Up to $21 million in licensing fees; ◦ $11 million payable

Antares Pharma (ATRS) Q3 Earnings Match Estimates
04 Nov, 2021 Yahoo! Finance

Antares Pharma (ATRS) delivered earnings and revenue surprises of 0.00% and -0.69%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Antares Pharma Reports Third Quarter 2021 Financial and Operating Results
04 Nov, 2021 Yahoo! Finance

Increased Revenue 20% Year-Over-Year to $48.2 Million Net Income of $5.4 Million, or $0.03 Per Basic and Diluted Earnings Per Share EWING, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today reported financial and operating results for the third quarter ended September 30, 2021 with record revenue of $48.2 million and net income of $5.4 million, or $0.03 per basic and diluted earnings per share. Robert F. Apple, P

Antares Pharma (ATRS) Reports Next Week: What to Expect
28 Oct, 2021 Yahoo! Finance

Antares Pharma (ATRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Antares Pharma Announces Appointment of Carmen Volkart to its Board of Directors
28 Oct, 2021 Yahoo! Finance

EWING, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced the appointment of Carmen Volkart to its Board of Directors. Ms. Volkart will also serve as a Member of the Audit Committee. Ms. Volkart is a seasoned medical device executive with extensive finance and operations experience at publicly traded and private companies. Since 2018, she has served as the Chief Financial Officer of NatureWorks, LLC. Pr

What Kind Of Shareholders Hold The Majority In Antares Pharma, Inc.'s (NASDAQ:ATRS) Shares?
27 Oct, 2021 Yahoo! Finance

Every investor in Antares Pharma, Inc. ( NASDAQ:ATRS ) should be aware of the most powerful shareholder groups...

Antares Pharma Announces Oral Presentation at the 22nd Annual Fall Scientific Meeting of SMSNA
25 Oct, 2021 Yahoo! Finance

EWING, N.J., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced that an abstract on XYOSTED®, a subcutaneous testosterone enanthate injection, was accepted as on oral presentation at the 22nd Annual Fall Scientific Meeting of SMSNA in Scottsdale, AZ on October 21-24, 2021. The abstract entitled “Subcutaneous Testosterone Enanthate and the Effect of Body Mass Index on Serum Testosterone in Men with Testosteron

We Did The Math IHE Can Go To $230
25 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares US.

Antares Pharma to Report Third Quarter 2021 Financial and Operating Results
21 Oct, 2021 Yahoo! Finance

EWING, N.J., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) (the “Company”), a specialty pharmaceutical company, today announced it will release its third quarter 2021 financial and operating results on Thursday, November 4, 2021, before the market opens. Antares will host a conference call on Thursday, November 4, 2021 at 8:30am ET to discuss the results. The dial-in numbers are (800) 353-6461 for domestic callers and (334) 323-0501 for international callers. The conferen

Lipocine, Antares Ink Licensing Pact For Testosterone Replacement Therapy In US
18 Oct, 2021 FinancialContent

Lipocine Inc(NASDAQ: LPCN) hasentered into an exclusive licensing agreementwithAntares Pharma ...

Antares Pharma Initiates Phase I Study For ATRS-1902 For Adrenal Crisis Rescue
30 Sep, 2021 FinancialContent

Pharmacokinetic data results expected in 1Q 2022

5 Value Stocks To Watch In The Healthcare Sector
27 Sep, 2021 FinancialContent

The Meaning Behind Value Stocks A value stock traditionally has a lower price when compared to stock prices of companies in the same ...

Analysts See 18% Gains Ahead For SMLF
22 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares MSCI USA Small-Cap Multifactor ETF (SMLF), we found that the implied analyst target price for the ETF based upon its underlying holdings is $63.71 per unit.

Antares Pharma to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
08 Sep, 2021 FinancialContent

Antares Pharma, Inc (ATRS) is a NASDAQ Common Stock listed in , ,

970x250